Changes

AstraZeneca is has been a [[ALEC Corporations|corporate member]] of the [[American Legislative Exchange Council]] (ALEC) and of its [[Health and Human Services Task Force]].<ref name="HHSNOLA">American Legislative Exchange Council, [http://www.commoncause.org/atf/cf/%7BFB3C17E2-CDD1-4DF6-92BE-BD4429893665%7D/35-day_mailing_hhs%20New%20Orleans.pdf HHS Task Force, June 29, 2011], organizational membership spreadsheet, June 29, 2011, p. 32, obtained and released by Common Cause April 2012</ref> Mark DiMaio, Associate Director of State Government Affairs at AstraZeneca, is the [[ALEC State Chairmen|ALEC State corporate co-chair]] of Delaware.<ref name="Corporate Chairs">American Legislative Exchange Council, "Solutions for the States," 38th Annual Meeting agenda, on file with CMD, August 3-6, 2011</ref> His legislative counterpart in Delaware is Rep. [[Daniel Short]] (R-39).
<ref name="Legislative Chairs">American Legislative Exchange Council, [http://www.alec.org/AM/Template.cfm?Section=State_Chairmen&Template=/CM/HTMLDisplay.cfm&ContentID=13614 ALEC State Chairmen], organization website, accessed June 30, 2011</ref> The company '''confirmed in response to an April 2013 shareholder question that it decided not to renew its membership in ALEC's task force'''.<ref>ShareAction, [http://shareaction.org/lobbying_agms#astrazeneca Astra Zeneca], organizational website, accessed August 2014.</ref> Please see [[Corporations that Have Cut Ties to ALEC]] for more.